Eli Lilly (LLY) Equity Average (2009 - 2026)

Eli Lilly has reported Equity Average for 18 years, with the latest figure at $28.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 3082.08% year-over-year to $28.9 billion; the trailing twelve-month figure through Mar 2026 stood at $28.9 billion (up 3082.08% YoY), and the FY2025 full-year result was $13.4 billion, up 1067.87% from the prior year.
• Equity Average for Q1 2026 stood at $28.9 billion, up from $25.2 billion in the prior quarter.
• The five-year high for Equity Average was $28.9 billion in Q1 2026, with the low at -$4.3 billion in Q3 2022.
• Historically, Equity Average has averaged $2.0 billion across 5 years, with a median of -$1.5 billion in 2023.
• Annual changes were most pronounced in 2022 — Equity Average slumped 311.17% — and 2025, when it soared 3176.62%.
• Eli Lilly's Equity Average stood at -$2.1 billion in 2022, then grew by 27.27% to -$1.5 billion in 2023, then jumped by 46.45% to -$818.8 million in 2024, then soared by 3176.62% to $25.2 billion in 2025, then grew by 14.58% to $28.9 billion in 2026.
• The last three Equity Average figures came in at $28.9 billion (Q1 2026), $25.2 billion (Q4 2025), and $11.9 billion (Q3 2025), per Business Quant data.